Mogamulizumab-Kpkc
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.
Journal: Journal of investigative medicine high impact case reports
Published: August 19, 2023
Unveiling the hidden struggles: Exploring the profound impact of advanced stage cutaneous T-cell lymphoma on quality of life.
Journal: Skin health and disease
Published: June 10, 2023
Strategies for Glycoengineering Therapeutic Proteins.
Journal: Frontiers in chemistry
Published: January 26, 2022
Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-cell lymphoma.
Journal: JAAD case reports
Published: January 17, 2022
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Journal: PharmacoEconomics
Published: September 26, 2021
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Journal: Drug design, development and therapy
Published: March 27, 2020
Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
Journal: Journal of the advanced practitioner in oncology
Published: November 01, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2019
Pharmaceutical Approval Update.
Journal: P & T : a peer-reviewed journal for formulary management
Published: October 02, 2018
CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis.
Journal: The Journal of dermatology
Published: August 05, 2014
Last Updated: 04/28/2026